| Bioactivity | DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days)[1]. |
| Target | IC50: 0.25 μg/mL (MRSA ATCC 43300) |
| Name | DHFR-IN-9 |
| Formula | C19H16N6S |
| Molar Mass | 360.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhu Z, et al. Exploration and Biological Evaluation of 1, 3-Diamino-7 H-pyrrol [3, 2-f] quinazoline Derivatives as Dihydrofolate Reductase Inhibitors[J]. Journal of Medicinal Chemistry, 2023.. . . |